High-Purity Inhalable Insulin Particles Manufacturing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing insulin particles for pulmonary delivery often result in low purity, high impurity levels, and particle sizes that are not optimal for effective absorption, leading to inefficient delivery and potential inflammatory responses.
Innovation Solution
A method involving dissolving insulin in an acidic solution, titrating with a buffer to form micronized particles, stabilizing with ethanol, and concentrating to achieve particles with a mean diameter of 1-2 μm, resulting in high-purity insulin particles with less than 2% insulin-related impurities and 0.03% solvent impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional methods are used to produce insulin particles for pulmonary delivery, then the production process is simple, but the purity is low and impurity levels are high
Solution Approach 1:
The production process is divided into multiple sequential steps: dissolving insulin in acidic solution, titrating with buffer to precipitate particles, stabilizing with ethanol, concentrating, and washing. Each step isolates and controls a specific aspect of particle formation and purification, enabling high purity (>98%) while maintaining manageable process complexity through systematic breakdown of the manufacturing workflow.
2Manufacturing precision
If conventional methods are used to produce insulin particles, then the manufacturing process is straightforward, but particle sizes are not optimal for effective absorption
Solution Approach 1:
The patent controls particle size (achieving 1-2 μm mean diameter) by adjusting critical process parameters: acidic solution pH (1.5-3.0), buffer solution pH (4.5-7.5), and ethanol concentration (50-90% v/v). These parameter optimizations enable precise particle size control for optimal pulmonary absorption while maintaining straightforward manufacturing through conventional equipment and well-understood chemical processes.
3Reliability
If conventional methods are used to produce insulin particles, then the production is simple, but absorption efficiency is poor and inflammatory risk increases
Solution Approach 1:
The patent performs preliminary stabilization of insulin particles with ethanol before pulmonary delivery, which protects the particles from aggregation and degradation. This preliminary action ensures optimal particle characteristics (size, purity, stability) are achieved before administration, thereby guaranteeing high absorption efficiency and reduced inflammatory risk while using a relatively simple process workflow.
4Manufacturing precision
If high-purity insulin particles are produced through multiple purification steps, then purity is high, but production time and complexity increase
Solution Approach 1:
The patent combines multiple functions into integrated process steps: the titration step simultaneously precipitates insulin particles and begins purification by separating them from soluble impurities; the ethanol stabilization step simultaneously stabilizes particles and prepares them for concentration; the concentration and washing steps are combined to achieve final purification in sequence. This merging of functions achieves >98% purity (insulin-related impurities <2%, solvent impurities <0.03%) while minimizing production time through efficient multi-functional process design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method produces insulin particles with high purity (>98%) and low impurities, achieving efficient pulmonary delivery with improved absorption and reduced inflammatory risk, suitable for both metered dose inhalation and dry powder formulations.
Implementation Method 1
dissolving an insulin raw material in an acidic solution (e.g., a mixture of water and methanol) to form a dissolved insulin solution
Implementation Method 2
titrating the dissolved insulin solution with a buffer solution to form a suspension comprising insulin particles
Implementation Method 3
stabilizing the insulin particles with ethanol
Implementation Method 4
concentrating; and washing with ethanol and concentrating to obtain insulin particles
Data Source
AI summary
A high-purity inhalable insulin material, used for preparing a pulmonary pharmaceutical product, includes insulin particles having a particle size at the micrometer level and having the following characteristics: (i) the purity of insulin is not less than 96% on the dried basis; (ii) the total amount of insulin-related impurities is not more than 2%; (iii) the total amount of solvent impurities, which is not a co-solvent formulation component for a pulmonary product, is not more than 0.03%; and (iv) the total amount of non-solvent impurities is not more than 0.3%. Up to 99% by volume of the insulin particles in the inhalable insulin have a particle size of less than 5 μm, based on the total volume of the insulin particles. A high-efficiency method prepares high-purity inhalable insulin material. The yield rate for the high-efficiency method is 75 to 85% or more.